InsidersTradesSigma
Follow the IMARA Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, IMARA Inc. has logged 38 insider filings. The latest transaction was filed on 23 February 2023 (Acquisition). Among the most active insiders: Leonard Braden Michael. Every trade is free.
38
Insider Decl.
n/a
Thresholds
€45m
17 ops.
Buy Volume
€10m
18 ops.
Sell Volume
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 February 2023
Declarations38 total
8,194 shares@ US$5.249100.0% of flowCommon stock, par value $0.001 per shareSEC:0001493152-23-005870:0
Canonical exit: 22 May 2023 (T+90)
9,856 shares@ US$4.6776.9% of flowCommon StockSEC:0001209191-23-012016:0
32,861 shares@ US$4.6677.9% of flowCommon StockSEC:0001209191-23-012015:0
3,596 shares@ US$3.9223.1% of flowCommon StockSEC:0001209191-23-005996:0
11,313 shares@ US$3.9122.1% of flowCommon StockSEC:0001209191-23-005993:0
629,297 shares@ US$3.998280.2% of flowCommon StockSEC:0001104659-23-001465:0
Canonical exit: 3 Apr 2023 (T+90)
1,250,000 shares@ US$4.0045.2% of flowCommon StockSEC:0001567619-23-000570:0
1,250,000 shares@ US$4.0045.8% of flowCommon StockSEC:0001567619-23-000371:0
20,000 shares@ US$4.040.7% of flowCommon StockSEC:0001567619-22-022154:0
157 shares@ US$4.040.0% of flowCommon StockSEC:0001567619-22-022103:0
1,078 shares@ US$4.060.0% of flowCommon StockSEC:0001567619-22-022014:0
10,600 shares@ US$3.751.3% of flowCommon StockSEC:0001104659-22-126294:0
Canonical exit: 8 Mar 2023 (T+90)
11,342 shares@ US$3.951.6% of flowCommon StockSEC:0001104659-22-110940:0
Canonical exit: 18 Jan 2023 (T+90)
145,672 shares@ US$3.3616.9% of flowCommon StockSEC:0001104659-22-110004:0
Canonical exit: 15 Jan 2023 (T+90)
83,199 shares@ US$1.108710.3% of flowCommon StockSEC:0001567619-22-013154:0
Canonical exit: 14 Sept 2022 (T+90)
30,800 shares@ US$1.13563.8% of flowCommon StockSEC:0001567619-22-012440:0
Canonical exit: 1 Sept 2022 (T+90)
15,000 shares@ US$1.17182.0% of flowCommon StockSEC:0001567619-22-011163:0
Canonical exit: 14 Aug 2022 (T+90)
552,000 shares@ US$1.4083.9% of flowCommon StockSEC:0001567619-22-008867:0
Canonical exit: 20 Jul 2022 (T+90)
439,088 shares@ US$1.069150.7% of flowCommon StockSEC:0001209191-22-023686:0
50,398 shares@ US$1.3052.9% of flowCommon StockSEC:0001209191-22-012399:0
Canonical exit: 19 May 2022 (T+90)
19,552 shares@ US$1.2019.0% of flowCommon StockSEC:0001209191-22-011049:0
Canonical exit: 16 May 2022 (T+90)
8,753 shares@ US$1.299.1% of flowCommon StockSEC:0001209191-22-009391:0
Canonical exit: 11 May 2022 (T+90)
131,400 shares0Common StockSEC:0001209191-22-005942:0
34,100 shares0Common StockSEC:0001209191-22-006037:0
39,350 shares0Common StockSEC:0001209191-22-005926:0
25 of 38 declarations
关于 IMARA Inc.
IMARA Inc.（股票代码：IMRA）是一家在美国纳斯达克市场上市的生物制药公司。对于法语投资者而言，它属于临床阶段生物技术公司中高风险、高回报的细分市场，而非商业阶段的制药平台。该公司于2016年1月在特拉华州注册成立，主要办事处位于马萨诸塞州波士顿，SEC备案文件也提及了马萨诸塞州布鲁克林的业务地址。IMARA于2020年3月完成首次公开募股，这突显了其相对较新的公开市场历史以及对外部融资以支持研发的依赖。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1672619/000156459022027795/imra-10q_20220630.htm?utm_source=openai)） 历史上，IMARA专注于开发用于罕见遗传性血红蛋白疾病的新型口服疗法，特别是镰状细胞病和β-地中海贫血。其主要项目是tovinontrine（IMR-687），一种高度选择性的PDE9抑制剂，设计为口服、每日一次、可能具有疾病修饰作用的治疗方法。该公司还提及了IMR-261，一种与Nrf2激活相关的口服资产。在SEC披露中，IMARA始终将自己描述为一家早期生物技术公司，面临该行业标准的开发风险：临床试验执行、监管批准、知识产权保护、竞争以及筹集额外资金的需求。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1672619/000156459022010216/imra-10k_20211231.htm?utm_source=openai)） 从竞争角度来看，IMARA瞄准了罕见血液疾病中的一个专业利基市场。这个利基市场在科学和商业上都极具吸引力，但也非常严苛：成功取决于明确的临床疗效、可接受的安全性以及可信的监管批准途径。IMARA的战略围绕着一种口服、差异化的机制构建，该机制可能解决疾病进展问题，但它仍然是一家与规模更大、资金更充足的制药和生物技术集团竞争的小盘生物技术公司。这意味着投资案例始终是高度二元化和数据驱动的。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1672619/000156459022010216/imra-10k_20211231.htm?utm_source=openai)） 最近最重要的进展发生在2022年4月5日，当时IMARA宣布tovinontrine的Ardent和Forte 2b期试验中期结果令人失望。根据这些发现，该公司停止了tovinontrine在镰状细胞病和β-地中海贫血方面的进一步开发，以及相关研究。2023年2月，IMARA宣布股东已批准其与Enliven Therapeutics的合并，这标志着其战略从之前的独立临床项目轨迹发生了重大转变。对于投资者而言，关键的启示是IMRA的故事变成了临床挫折后企业重组的故事，而非成功的后期生物技术商业化故事。（[globenewswire.com](https://www.globenewswire.com/news-release/2022/04/05/2416438/0/en/Imara-Announces-Results-of-Interim-Analyses-of-Tovinontrine-IMR-687-Phase-2b-Clinical-Trials-in-Sickle-Cell-Disease-and-Beta-Thalassemia.html?utm_source=openai)）
